AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Myomo to Report First Quarter 2019 Results on May 13, 2019

May 7, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2019--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will release its financial results for the first quarter ended March 31, 2019 on Monday, May 13, 2019, before the US markets open.

The Company will host a conference call on Monday, May 13, 2019 at 8:30 a.m. EDT featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and David Henry, Chief Financial Officer. The conference call, webcast can be accessed through Myomo’s Investor Relations page. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

To dial into the conference call, please dial 1-877-270-2148 from the U.S. or 1-412-902-6510 internationally. A replay of the conference call will be available approximately one hour after completion of the live conference call at the Investor Relations page. A dial-in replay of the call will be available until May 27, 2019; please dial 1-877-344-7529 from the U.S. or 1-412-317-0088 internationally and provide the passcode of 10130705.

About Myomo
Myomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190507005148/en/

CONTACT: For Myomo:

ir@myomo.comInvestor Relations:

Vivian Cervantes

PCG Advisory, Inc.

646-863-6274

vivian@pcgadvisory.comPublic Relations:

Matter Communications

Sarah Karr

978-518-4817

myomo@matternow.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: TECHNOLOGY HARDWARE OTHER TECHNOLOGY HEALTH BIOTECHNOLOGY MEDICAL DEVICES

SOURCE: Myomo, Inc.

Copyright Business Wire 2019.

PUB: 05/07/2019 08:00 AM/DISC: 05/07/2019 08:01 AM

http://www.businesswire.com/news/home/20190507005148/en